Beta Blocking Agent Use
Beta-blocking agents, also known as beta-adrenergic blocking agents, are a class of medications widely prescribed to manage various cardiovascular conditions. These drugs primarily work by interfering with the effects of adrenaline and noradrenaline, naturally occurring stress hormones, on specific receptors throughout the body. Their use is critical in regulating heart function and blood pressure, thereby improving patient outcomes for a range of diseases.
Biological Basis
The primary biological mechanism of beta-blocking agents involves blocking beta-adrenergic receptors. These receptors are part of the sympathetic nervous system, which controls the "fight or flight" response. By blocking these receptors, beta-blockers reduce heart rate, lower blood pressure, and decrease the heart's workload. Genetic variations in genes such as the beta1-adrenoceptor gene have been studied for their potential influence on physiological responses, such as aerobic power in individuals with coronary artery disease. [1]
Clinical Relevance
Beta-blocking agents are clinically relevant in treating a variety of conditions, including hypertension, angina pectoris, cardiac arrhythmias, heart failure, and anxiety. They are a common component of hypertension treatment strategies. [2] Individual responses to beta-blockers can vary significantly due to genetic factors. For instance, polymorphisms have been shown to alter the acute blood pressure response to aerobic exercise, particularly among men with hypertension. [3] Understanding these genetic influences can help personalize treatment to optimize efficacy and minimize adverse effects.
Social Importance
The widespread use of beta-blocking agents underscores their significant social importance in public health. By effectively managing chronic and acute cardiovascular conditions, these medications contribute to a reduction in morbidity and mortality, enhance the quality of life for millions of people worldwide, and alleviate the burden of cardiovascular disease on healthcare systems.
Methodological and Statistical Constraints
Studies investigating the genetic influences on traits often face limitations in statistical power, particularly when attempting to detect modest genetic effects from variants that individually contribute small proportions to phenotypic variation. Despite the application of large sample sizes and meta-analysis techniques, the extensive multiple testing inherent in genome-wide association studies (GWAS) necessitates very stringent significance thresholds. This requirement can lead to a lack of genome-wide significance for true, but subtle, associations, implying that some genuine genetic influences may remain undetected and hindering a complete understanding of the genetic architecture of the trait. [2]
Furthermore, the validity of identified genetic associations is heavily dependent on successful replication in independent cohorts, yet many initial findings require further external validation. The use of genotyping arrays with partial coverage of genetic variation, such as older Affymetrix 100K chips, or reliance on imputation from reference panels like HapMap, can restrict the ability to comprehensively survey all common variants or replicate previously reported associations. While imputation methods are employed to infer missing genotypes and facilitate comparisons across studies, they introduce potential error rates and can impact the confidence and reliability of reported associations. [4]
Generalizability and Phenotype Heterogeneity
A significant limitation in many genetic studies is the predominant focus on populations of white European ancestry, which restricts the generalizability of findings to other ethnic groups. Genetic associations can exhibit racial differences, meaning that variants identified in one population may not have the same effect, or even be present, in others. This lack of diversity in study cohorts limits a comprehensive understanding of genetic influences across the global population and underscores the need for more inclusive research to capture the full spectrum of genetic variability and its impact. [2]
The definition and measurement of complex phenotypes can also introduce heterogeneity and bias into genetic analyses. For instance, averaging physiological traits over extended periods, sometimes spanning decades and involving different equipment, may obscure age-dependent genetic effects or introduce misclassification, despite efforts to reduce regression dilution bias. Additionally, analyses often pool sexes to enhance statistical power, potentially missing sex-specific genetic associations that could be crucial for a complete understanding of trait biology. [2]
Environmental Confounders and Unexplored Interactions
Genetic influences on complex traits are frequently modulated by environmental factors, yet many studies do not explicitly investigate these gene-environment interactions. The impact of a genetic variant can be context-specific, with its effect size or even direction potentially varying based on lifestyle, diet, or other environmental exposures. Failing to account for such interactions means that the full biological pathways and regulatory mechanisms underlying observed associations remain incompletely characterized, contributing to the challenge of explaining the 'missing heritability' of complex traits. [2]
Beyond direct gene-environment interactions, various environmental or lifestyle confounders may influence observed genetic associations if not adequately adjusted for in statistical models. While studies often control for known covariates, unmeasured or unknown factors can still distort genetic effect estimates. The current understanding of the genetic landscape for many complex traits remains incomplete, with many associations representing exploratory findings that require further functional validation to elucidate their precise biological roles and interactions. [4]
Variants
Genetic variations play a crucial role in influencing an individual's susceptibility to various diseases and their response to pharmacological treatments, including beta-blocking agents. The genes and their associated variants discussed here are implicated in a range of biological processes, from cellular signaling and metabolism to development and immune function, all of which can indirectly or directly impact cardiovascular health and treatment efficacy.
The PRDM8 gene encodes a protein involved in gene regulation and chromatin remodeling, influencing processes like cell differentiation and metabolism, while FGF5 produces a fibroblast growth factor involved in cell growth and development. Variants like rs10857147 and rs13125101 near these genes may modulate these pathways, potentially affecting cardiovascular risk factors or the body's response to medications such as beta-blocking agents. The FES gene, encoding a protein tyrosine kinase, is involved in cell signaling pathways that regulate cell growth, differentiation, and immune responses, with variants such as rs7183988 potentially altering these crucial cellular communications. SH2B3 is an adaptor protein that regulates cytokine and growth factor signaling, making variants like rs7310615 relevant to immune function and potentially inflammatory processes that can influence cardiovascular health. Finally, NOS3 (Endothelial Nitric Oxide Synthase) is critical for producing nitric oxide, a key molecule for vasodilation and maintaining vascular health, where variants like rs3918226 could affect blood pressure regulation and the efficacy of drugs targeting the cardiovascular system. [4] Such genetic variations are often explored in large-scale studies to understand their contribution to complex traits and drug responses. [5]
The CDKN2B-AS1 gene, also known as ANRIL, produces a long non-coding RNA that regulates the expression of neighboring genes involved in cell cycle control and senescence, including CDKN2A and CDKN2B. Variants such as rs10757272, rs2891168, and rs6475608 within this region have been linked to an increased risk of coronary artery disease and type 2 diabetes, suggesting an influence on cellular aging and metabolic regulation that could impact cardiovascular health and the management of conditions treated with beta-blockers. CASZ1 is a zinc finger transcription factor important for neural and cardiac development, and its variants, including rs880315 and rs12046278, may play a role in cardiac structure or function. Similarly, LINC01438 is a long intergenic non-coding RNA whose precise functions are still being elucidated, but non-coding RNAs are increasingly recognized for their regulatory roles in gene expression and cellular processes, making variants like rs75725917 and rs2200733 potential modulators of disease risk and treatment response. These genetic factors contribute to the complex interplay of pathways that influence disease susceptibility and individual responses to pharmacological interventions. [4]
The CNNM2 gene encodes a protein involved in magnesium transport, a vital process for numerous cellular functions, including muscle contraction, nerve signaling, and blood pressure regulation. Variants such as rs1926032 in CNNM2 may influence magnesium homeostasis and, consequently, blood pressure control, which is a primary target of beta-blocking agents. LSP1 (Lymphocyte-Specific Protein 1) is an actin-binding protein predominantly expressed in leukocytes, playing a role in cytoskeletal organization and immune cell function. Variations like rs569550 and rs1973765 could affect inflammatory responses or immune cell behavior, which can indirectly influence cardiovascular disease progression. The WNT2B gene is part of the Wnt signaling pathway, a highly conserved network critical for embryonic development, cell proliferation, and tissue homeostasis, with variants like rs10776752 potentially impacting these fundamental biological processes. [6] Understanding these genetic influences can help personalize therapeutic strategies, including those involving beta-blockers, by accounting for individual genetic predispositions. [7]
Key Variants
Causes of Beta Blocking Agent Use
The use of beta-blocking agents is primarily driven by the presence of underlying cardiovascular and metabolic conditions that necessitate their therapeutic effects. These conditions stem from a complex interplay of genetic predispositions, environmental exposures, developmental factors, and the presence of other health issues.
Genetic Underpinnings of Cardiovascular and Metabolic Health
Genetic factors play a significant role in an individual's susceptibility to conditions for which beta-blockers are prescribed, such as hypertension, dyslipidemia, and heart rate abnormalities. Studies have identified common genetic variants contributing to polygenic dyslipidemia, indicating a complex genetic architecture underlying lipid metabolism disorders. [8] Furthermore, specific genes are implicated in cardiovascular function; for instance, polymorphisms in the beta1-adrenoceptor gene have been associated with aerobic power in coronary artery disease, directly linking genetic variation to a pathway modulated by beta-blockers. [2] Genetic variations at the endothelial nitric oxide synthase locus are also related to brachial artery vasodilator function, highlighting the genetic influence on vascular health. [2]
Other genetic influences include the acetylcholine receptor M2 (CHRM2) gene, where polymorphisms are associated with heart rate recovery after maximal exercise, suggesting a genetic basis for autonomic regulation of heart rate. [2] Additionally, genes like PDE5 and PDE5A are critical for vascular smooth muscle cell function by degrading cGMP and potentially mediating the growth-promoting effects of Angiotensin II, thereby influencing blood vessel tone and blood pressure regulation. [2] Loci related to metabolic pathways, including LEPR, HNF1A, IL6R, and GCKR, have also been associated with plasma C-reactive protein, indicating genetic links to inflammatory processes and metabolic syndrome that can precede cardiovascular disease. [9]
Environmental and Lifestyle Contributors
Environmental and lifestyle factors are crucial determinants in the development and progression of conditions that often require beta-blocking agents. Habits such as smoking are consistently identified as significant covariates in studies of cardiovascular and metabolic traits, impacting endothelial function and overall cardiovascular health. [2] Dietary patterns and alcohol consumption also contribute to the risk profile; for example, specific dietary studies underscore the importance of nutritional factors in cardiovascular health [8] while alcohol use is noted as a relevant factor in biomarker studies. [4] Physical activity levels, as assessed through treadmill exercise responses and heart rate recovery, are also influenced by and can influence cardiovascular health, with lower fitness often correlating with higher risk for conditions managed by beta-blockers. [2]
Interactions and Age-Related Dynamics
The development of conditions necessitating beta-blocker use is often a result of complex gene-environment interactions, where genetic predispositions are modulated by external factors over time. For instance, while genetic associations for various traits are studied, researchers frequently adjust for covariates like smoking, diabetes, and hypertension treatment, implicitly acknowledging that environmental and lifestyle choices can modify the expression or impact of genetic variants. [2] Furthermore, age is a critical factor influencing cardiovascular traits, and it is recognized that age-dependent gene effects may exist, meaning that genetic influences on certain phenotypes can change or manifest differently across an individual's lifespan. [2] This suggests a developmental component where the timing and duration of environmental exposures can interact with genetic backgrounds to shape an individual's risk profile for conditions requiring beta-blockers.
Influence of Comorbidities and Clinical Factors
Existing health conditions and various clinical factors are strong drivers for the prescription of beta-blocking agents. Comorbidities such as diabetes, intrinsic renal disease, secondary hypertension, and extreme obesity significantly increase an individual's risk for cardiovascular complications, making beta-blocker use a common therapeutic strategy. [10] Prevalent cardiovascular disease, including stroke, heart failure, and myocardial infarction, directly indicates the need for these medications to manage symptoms and prevent further events. [2] Additionally, the use of other medications, such as hypertension treatment, lipid-lowering therapies, or hormone replacement therapy, often reflects an existing clinical need to manage cardiovascular risk factors, which can either lead to or be co-prescribed with beta-blocking agents as part of a comprehensive treatment plan. [2]
Adrenergic and Neurohormonal Signaling in Cardiovascular Control
Beta-blocking agents primarily modulate the intricate adrenergic signaling pathways that regulate cardiovascular function. These agents exert their effects by antagonizing beta-adrenergic receptors, influencing heart rate, contractility, and vascular tone. Polymorphisms within the _beta1-adrenoceptor_ gene have been associated with aerobic power in individuals with coronary artery disease, suggesting genetic variability can impact the receptor's function and, consequently, the efficacy of adrenergic modulation. [1] Beyond direct adrenergic effects, the cardiovascular system is also regulated by other neurohormonal pathways, such as the renin-angiotensin-aldosterone system (RAAS), where angiotensin-converting enzyme gene polymorphisms are linked to left ventricular mass in hypertension. [11]
Furthermore, these agents interact with broader regulatory networks, including those involving nitric oxide and cyclic guanosine monophosphate (cGMP) signaling. Common genetic variations at the endothelial nitric oxide synthase locus are associated with brachial artery vasodilator function, highlighting the role of nitric oxide in vascular health. [8] Angiotensin II, a key component of the RAAS, can increase the expression of phosphodiesterase 5A in vascular smooth muscle cells, thereby antagonizing cGMP signaling and influencing vascular tone. [12] This interplay between adrenergic, RAAS, and cGMP pathways demonstrates a complex system-level integration where beta-blockers contribute to overall cardiovascular homeostasis.
Metabolic Pathways and Lipid Homeostasis
Beta-blocking agent use often occurs in the context of broader cardiovascular disease management, which involves intricate metabolic pathways, particularly those related to lipid homeostasis. The mevalonate pathway, crucial for cholesterol biosynthesis, is regulated by 3-hydroxy-3-methylglutaryl-CoA reductase (_HMG-CoA reductase_), an enzyme whose activity and degradation rate are influenced by its oligomerization state. [13] Genetic variants affecting alternative splicing of _HMGCR_ exon13 have been associated with LDL-cholesterol levels, impacting the efficiency of this critical metabolic step. [14]
Other key players in lipid metabolism include apolipoprotein C3 (_APOC3_) and angiopoietin-like proteins (_ANGPTL3_ and _ANGPTL4_). A null mutation in human _APOC3_ can lead to a favorable plasma lipid profile and confer cardioprotection [15] while _ANGPTL3_ regulates lipid metabolism and _ANGPTL4_ variations are associated with reduced triglycerides and increased HDL. [16] The transcription factor _SREBP-2_ is also involved in regulating isoprenoid and adenosylcobalamin metabolism, suggesting a link between cholesterol synthesis and other metabolic processes. [17] These pathways collectively highlight the metabolic context relevant to cardiovascular health and therapeutic interventions.
Cellular Stress, Inflammation, and Endothelial Function
Cellular responses to stress and inflammation are critical mechanisms in cardiovascular disease pathogenesis, which beta-blockers may indirectly influence. The mitogen-activated protein kinase (_MAPK_) pathway is a central signaling cascade activated in response to various stimuli, with its activation affected by factors such as age and acute exercise in human skeletal muscle. [2] Inflammatory cytokines can transcriptionally regulate the intercellular adhesion molecule-1 (_ICAM-1_) gene in human endothelial cells, primarily through essential roles of a variant _NF-kappa B_ site and _p65_ homodimers. [18]
The _ABO_ histo-blood group antigen has been associated with soluble _ICAM-1_, linking genetic predispositions to inflammatory markers and cardiovascular risk. [19] The _ABO_ blood group system itself has been studied in relation to age, sex, risk factors, and cardiac infarction, indicating a systems-level integration of genetic and environmental factors in disease development. [20] These mechanisms underscore the broader cellular and systemic environment in which cardiovascular interventions operate, with beta-blockers contributing to overall systemic stability.
Glucose Homeostasis and Diabetes-Related Mechanisms
The management of conditions requiring beta-blocking agents often involves consideration of glucose homeostasis and diabetes-related mechanisms due to common comorbidities. Insulin resistance and beta-cell function are key physiological parameters in the development of type 2 diabetes, often assessed through models like homeostasis model assessment. [21] Genetic variants, such as those in the transcription factor 7-like 2 (_TCF7L2_) gene, are known to confer risk of type 2 diabetes. [22]
Specific genes and their products play crucial roles in glucose metabolism, including hexokinase 1 (_HK1_), which shows an association with glycated hemoglobin in non-diabetic populations. [19] The zinc transporter _ZnT-8_ (_SLC30A8_), localized in insulin secretory granules, is vital for glucose-induced insulin secretion and beta-cell function. [23] Genetic studies have identified associations of multiple loci, including _CDKAL1_, _IGF2BP2_, _CDKN2A/B_, _HHEX_, _SLC30A8_, and _KCNJ11_, with susceptibility to type 2 diabetes, highlighting the complex polygenic nature of this metabolic disease and potential therapeutic targets. [24]
Therapeutic Role in Hypertension and Cardiovascular Outcome Improvement
Beta-blocking agents are established as a key therapeutic option for managing hypertension, a primary risk factor for adverse cardiovascular events. Evidence from randomized controlled trials, such as the NORDIL study, has rigorously compared beta-blockers with other antihypertensive classes like calcium antagonists and diuretics. This comparative research is crucial for understanding the prognostic value of beta-blocker use in reducing cardiovascular morbidity and mortality. The findings from such studies directly inform clinical applications, guiding treatment selection to improve long-term patient outcomes. [25]
Informing Treatment Strategies and Risk Management
The NORDIL trial, which included a substantial cohort of participants from Norway and Sweden, exemplifies the role of large-scale clinical investigations in shaping treatment strategies for hypertension. By evaluating beta-blockers against alternative agents, the study contributes to risk assessment and stratification for patients with hypertension. While specific personalized medicine approaches or detailed monitoring strategies are not described, the comparative efficacy data provides a foundation for clinicians to select appropriate therapies aimed at preventing cardiovascular complications. This highlights the importance of evidence from well-designed trials in optimizing patient care. [25]
Pharmacogenetics of Beta-Blocking Agent Use
Beta-blocking agents are a cornerstone in the management of various cardiovascular conditions, including hypertension, angina, arrhythmias, and heart failure. However, individual responses to these medications can vary widely, influenced by a complex interplay of genetic factors affecting drug metabolism, transport, and target interaction. Pharmacogenetics aims to elucidate these genetic underpinnings to optimize therapeutic outcomes and minimize adverse effects, moving towards a more personalized approach to prescribing beta-blockers.
Genetic Variability in Beta-Blocker Metabolism
The metabolism of beta-blockers, a critical determinant of drug exposure and efficacy, can be significantly influenced by genetic variations in drug-metabolizing enzymes. For instance, studies have highlighted how mutations in specific cytochrome P450 enzymes, such as alterations in the residue at position 481 of P450s 2a-4/5, can change enzyme activity and substrate specificity, potentially leading to varied drug clearance rates. [26] Similarly, phase II enzymes like Glutathione S-transferase omega 1 and Glutathione S-transferase omega 2 are also subject to pharmacogenomic variability, impacting the conjugation and detoxification pathways of many compounds, including potentially beta-blockers. [27] These genetic differences contribute to the observed "different metabolic phenotypes in humans," where individuals metabolize drugs at varying rates, thus influencing the drug's half-life and steady-state concentrations. [28] Consequently, patients with certain metabolic profiles may experience either subtherapeutic drug levels or an increased risk of adverse reactions due to altered systemic exposure.
Impact of Receptor Polymorphisms on Therapeutic Response
The effectiveness of beta-blockers is closely tied to the genetic makeup of their primary targets, particularly the beta-1 adrenoceptor. Polymorphisms within the beta1-adrenoceptor gene have been shown to influence physiological responses, such as aerobic power in individuals with coronary artery disease, directly affecting how patients respond to therapeutic interventions targeting this receptor. [1] Beyond the direct receptor, broader genetic variations can alter the acute blood pressure response to physiological stressors like aerobic exercise among men with hypertension, indicating a complex interplay of genetic factors in cardiovascular regulation. [2] These target-related genetic variants can modify the binding affinity of beta-blockers, alter downstream signaling pathways, or change receptor expression, ultimately leading to inter-individual differences in therapeutic efficacy and the magnitude of desired pharmacodynamic effects. Understanding these polymorphisms is crucial for predicting how well a patient might respond to a given beta-blocker therapy.
Clinical Considerations for Personalized Beta-Blocker Prescribing
Integrating pharmacogenetic insights into beta-blocker therapy offers a pathway toward more personalized and effective patient care. By identifying an individual's specific metabolic phenotype, based on variants in enzymes like P450s and glutathione S-transferases, clinicians could anticipate altered drug clearance and adjust initial dosing to achieve optimal therapeutic concentrations while minimizing the risk of adverse drug reactions. [26] Similarly, knowledge of beta1-adrenoceptor gene polymorphisms can guide drug selection, potentially favoring specific beta-blockers or alternative antihypertensive agents for patients predicted to have a suboptimal response due to genetic variations. [1] Although the research highlights specific genetic associations, the development of comprehensive clinical guidelines that incorporate these pharmacogenetic markers is an ongoing endeavor, aiming to move beyond empirical prescribing to a more genetically informed approach that maximizes patient benefit and safety.
References
[1] Defoor, J., et al. "The CAREGENE study: polymorphisms of the beta1-adrenoceptor gene and aerobic power in coronary artery disease." Eur Heart J, 2006, vol. 27, pp. 808-816.
[2] Vasan, R. S., et al. "Genome-wide association of echocardiographic dimensions, brachial artery endothelial function and treadmill exercise responses in the Framingham Heart Study." BMC Med Genet, 2007, vol. 8, no. Suppl 1, p. S2.
[3] Blanchard, B. E., et al. "RAAS polymorphisms alter the acute blood pressure response to aerobic exercise among men with hypertension." Eur J Appl Physiol, 2006, vol. 97, pp. 26-33.
[4] Benjamin, E. J., et al. "Genome-wide association with select biomarker traits in the Framingham Heart Study." BMC Med Genet, 2007, vol. 8, no. Suppl 1, p. S1.
[5] Kathiresan, Sekar, et al. "Common variants at 30 loci contribute to polygenic dyslipidemia." Nature Genetics, vol. 41, no. 1, 2009, pp. 56-65.
[6] Yang, Qiong, et al. "Genome-wide association and linkage analyses of hemostatic factors and hematological phenotypes in the Framingham Heart Study." BMC Medical Genetics, vol. 8, no. Suppl 1, 2007, p. S12. PMID: 17903294.
[7] Saxena, Richa, et al. "Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels." Science, vol. 316, no. 5829, 2007, pp. 1331-1336.
[8] Kathiresan, S., et al. "Common genetic variation at the endothelial nitric oxide synthase locus and relations to brachial artery vasodilator function in the community: the Framingham Heart Study." Circulation, vol. 114, no. 18, 2006, pp. 1928-1935.
[9] Ridker, Paul M., et al. "Loci related to metabolic-syndrome pathways including LEPR, HNF1A, IL6R, and GCKR associate with plasma C-reactive protein: the Women's Genome Health Study." American Journal of Human Genetics, vol. 82, no. 5, 2008, pp. 1185-1192.
[10] Wallace, Cathryn, et al. "Genome-wide association study identifies genes for biomarkers of cardiovascular disease: serum urate and dyslipidemia." American Journal of Human Genetics, vol. 82, no. 1, 2008, pp. 139-149.
[11] Celentano, A., et al. "Cardiovascular risk factors, angiotensin-converting enzyme gene I/D polymorphism, and left ventricular mass in systemic hypertension." Am J Cardiol, vol. 83, no. 8, 1999, pp. 1196-1200.
[12] Kim, D., et al. "Angiotensin II increases phosphodiesterase 5A expression in vascular smooth muscle cells: a mechanism by which angiotensin II antagonizes cGMP signaling." J Mol Cell Cardiol, vol. 38, no. 1, 2005, pp. 175-184.
[13] Cheng, H. H., et al. "Oligomerization state influences the degradation rate of 3-hydroxy-3-methylglutaryl-CoA reductase." J Biol Chem, vol. 274, no. 24, 1999, pp. 17171-17178.
[14] Burkhardt, R., et al. "Common SNPs in HMGCR in micronesians and whites associated with LDL-cholesterol levels affect alternative splicing of exon13." Arterioscler Thromb Vasc Biol, 2009.
[15] Pollin, T. I., et al. "A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection." Science, vol. 326, no. 5957, 2009, pp. 994-998.
[16] Koishi, R., et al. "Angptl3 regulates lipid metabolism in mice." Nat Genet, vol. 30, no. 2, 2002, pp. 151-157.
[17] Murphy, C., et al. "Regulation by SREBP-2 defines a potential link between isoprenoid and adenosylcobalamin metabolism." Biochem Biophys Res Commun, vol. 355, no. 2, 2007, pp. 359-364.
[18] Ledebur, H. C., and T. P. Parks. "Transcriptional regulation of the intercellular adhesion molecule-1 gene by inflammatory cytokines in human endothelial cells. Essential roles of a variant NF-kappa B site and p65 homodimers." J Biol Chem, vol. 270, no. 2, 1995, pp. 933-943.
[19] Pare, G., et al. "Novel association of ABO histo-blood group antigen with soluble ICAM-1: results of a genome-wide association study of 6,578 women." PLoS Genet, vol. 4, no. 7, 2008, e1000118.
[20] Medalie, J. H., et al. "Blood groups, myocardial infarction and angina pectoris among 10,000 adult males." N Engl J Med, vol. 285, no. 24, 1971, pp. 1348-1353.
[21] Matthews, D. R., et al. "Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man." Diabetologia, vol. 28, no. 7, 1985, pp. 412-419.
[22] Grant, S. F., et al. "Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes." Nat Genet, vol. 38, no. 3, 2006, pp. 320-323.
[23] Chimienti, F., et al. "Identification and cloning of a beta-cell-specific zinc transporter, ZnT-8, localized into insulin secretory granules." Diabetes, vol. 53, no. 9, 2004, pp. 2330-2337.
[24] Omori, S., et al. "Association of CDKAL1, IGF2BP2, CDKN2A/B, HHEX, SLC30A8, and KCNJ11 with susceptibility to type 2 diabetes in a Japanese population." Diabetes, vol. 57, no. 3, 2008, pp. 791-795.
[25] Kathiresan, S., et al. "Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans." Nat Genet, 2008.
[26] Matsunaga, T., et al. "Altering the Regiospecificity of Androstenedione Hydroxylase Activity in P450s 2a-4/5 by a Mutation of the Residue at Position 481." Biochemistry, vol. 34, no. 15, 1995, pp. 5054–9.
[27] Mukherjee, B., et al. "Glutathione S-Transferase Omega 1 and Omega 2 Pharmacogenomics." Drug Metabolism and Disposition: The Biological Fate of Chemicals, vol. 34, no. 7, 2006, pp. 1237–46.
[28] Assfalg, M., et al. "Evidence of Different Metabolic Phenotypes in Humans." Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 4, 2008, pp. 1420–24.